Dogwood Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2023


	December 31,		December 31,
	2023		2022
Accrued interest on preferred members’ interests	$	188,085	$	188,085
Accrued director fees		31,000		31,000
Accrued professional fees		27,550		11,600
Accrued compensation		—		159,704
Accrued clinical research costs		—		78,349
Other miscellaneous accrued expenses		—		1,360
	$	246,635	$	470,098